Jing Wu

Prof. Dr. Jing Wu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Annals of Medicine
Verified
Journal Article
Open access
XWXingxing Wu
Xingxing Wu
LQLin Qian
Lin Qian
KLKexin Liu
Kexin Liu
JWJing Wu
Jing Wu
ZSZhaowei Shan
Zhaowei Shan
Coeliac disease (CD), also known as gluten sensitive enteropathy, is an autoimmune intestinal disease induced by gluten in genetically susceptible individuals. Gluten is a common ingredient in daily diet and is one of the main environmental factors to induce coeliac disease. Adhering to gluten free diet (GFD) is an effective method for treating CD. Microbiota plays an extremely important role in maintaining human health, and diet is the main factor to regulate the composition and function of gut microbiota. Recent studies have shown that gluten metabolism is closely related to gastrointestinal tract (GIT) microbiota. With the increasing prevalence of coeliac disease, there is a need for alternative treatments to GFD. In this review, biological medication of gluten, relationship between gluten and gut microflora, effect of GFD on GIT microflora, and effect of probiotics on CD were reviewed. By analysing the research progress on relationship between gluten and gastrointestinal microbiome in coeliac disease, this review tried to explore the prospective and potential mechanism of microecological agents in treating coeliac disease.

1 July 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
XWXingxing Wu
Xingxing Wu
KLKexin Liu
Kexin Liu
QWQi Wu
Qi Wu
MWMao Wang
Mao Wang
XCXuelian Chen
Xuelian Chen
ZSZhaowei Shan
Zhaowei Shan
Aims. This study aims to investigate the potential biomarkers of inflammatory bowel disease (IBD) and IBD with damp-heat syndrome (IBD-DH) by metabolomics. Methods. Plasma and urine samples were collected from 15 healthy controls and 30 IBD patients, including 15 IBD-DH and 15 IBD with spleen deficiency syndrome (IBD-SD), which was coded as SF8G and SF70 according to the International Classification of Diseases Eleventh Revision (ICD-11) issued by World Health Organization. Pseudotargeted metabolomics method was used based on ultra-high-performance liquid chromatography-high-resolution mass spectrometry and triple-quadrupole mass spectrometry. Results. Under the condition of false discovery rate (FDR)1.0, and fold change (FC)>1.5 or<2/3, we found 57 plasma differential metabolites and 20 urinary differential metabolites in IBD. Then, with area under the curve (AUC)0.85 and FC2 or 0.3, 11 potential biomarkers were identified, such as acylcarnitine (ACar 20:4, ACar 18:1, and ACar 20:3), 3-indoleacetic acid, hippuric acid, and dehydroepiandrosterone sulfate, which is related to intestinal microbiota and immune response. However, less obvious differences were observed in IBD-DH when compared with IBD-SD. Under the condition of FDR1.0, and FC>1.5 or <2/3, we identified 16 plasma differential metabolites. In urine samples, IBD-DH and IBD-SD had the same metabolite pattern. With AUC0.80, 7 differential plasma metabolites, mainly glycerophospholipids, were identified in IBD-DH. Kyoto Encyclopedia of Genes and Genomes analysis indicated that metabolic pathways, such as citrate cycle and amino acids metabolism, were mainly responsible for the distinction between IBD and healthy controls, whereas glycerophospholipid metabolism perturbation was not only a manifestation of IBD but also an important pathway to distinguish two subtypes defined by traditional medicine, IBD-DH and IBD-SD. Conclusion. In this study, we found that several metabolites of aromatic acids and lipid derivatives could act as potential biomarkers to discriminate IBD from healthy controls. Glycerophospholipids metabolites might be used to differentiate IBD-DH from IBD-SD.

1 March 2023 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
QWQi Wu
Qi Wu
XWXingxing Wu
Xingxing Wu
MWMao Wang
Mao Wang
KLKexin Liu
Kexin Liu
YLYuge Li
Yuge Li
GMGenglin Mu
Genglin Mu
Background: Baicalin is an important active flavonoid isolated from the roots of Scutellaria baicalensis (S. baicalensis), a well-known traditional Chinese herb used in treating inflammatory bowel disease (IBD). The objectives of this study were to assess the potential benefit of baicalin in experimental colitis, as well as to investigate metabolic biomarkers of experimental colitis in conjunction with network pharmacology. Methods: Using a widely utilized network pharmacology technique, baicalin’s targets and pathways were predicted. Simultaneously, experimental colitis was induced by intrarectal administration of TNBS. Histopathology examinations were performed to confirm pathological changes. Plasma samples were examined by using an untargeted metabolomics technique based on ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS) to screen differential metabolites and associated metabolic pathways. Additionally, network pharmacology and integrated analysis of metabolomics were used to identify the primary targets. Results: Through network pharmacology research, tumor necrosis factor (TNF), interleukin 6 (IL6), serine/threonine-protein kinase (AKT1), and other 7 proteins were found to be the main targets of baicalin against IBD. The untargeted metabolomics results showed that 47 metabolites in glycerophospholipids and sphingolipid metabolism were involved as key pathways in the experimental colitis model group. 19 metabolites, including Sphingomyelin (SM d42:2, SM d42:1, SM d34:1), Lysophosphatidic acids (LPA 18:4), 1-Palmitoylglycerophosphocholine, and 17(18)-EpETE were demonstrated as key metabolites for baicalin to exert effects. Moreover, udp-glucose ceramide glucosyltransferase (UGCG), sphingomyelin synthase 1 (SGMS1), and sphingosine kinase (SPHK1) were predicted as sphingolipids-linked targets of baicalin against experimental colitis by integrative analysis. Conclusion: Based on these results, it implies that sphingolipid metabolism and sphingolipid signaling pathway might be acted as therapeutic mechanism for baicalin against experimental colitis.

28 October 2025 in Biomaterials
Verified
Journal Article
Closed access
ZSZhiting Sun
Zhiting Sun
MXMing Xu
Ming Xu
LNLu Nie
Lu Nie
CWChangrong Wang
Changrong Wang
JWJing Wu
Jing Wu
HSHuijuan Song
Huijuan Song

1 November 2024 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
QWQi Wu
Qi Wu
KLKexin Liu
Kexin Liu
RHRuijuan Hou
Ruijuan Hou
XWXingxing Wu
Xingxing Wu
XRXiaoyu Ruan
Xiaoyu Ruan
GMGenglin Mu
Genglin Mu
Purpose: Inflammatory bowel disease (IBD) is a serious disease that affects the metabolism and inflammatory responses of human beings. From the perspective of traditional Chinese medicine, damp-heat syndrome is one of the main syndromes of IBD. Rhizoma Paridis, also known as the root of Paris polyphylla, a well-known herbal medicine used in China, is used to treat IBD with damp-heat syndrome (IBD-DH). However, uncertainty still exists regarding the underlying mechanisms and the impact of Rhizoma Paridis on IBD-DH. Methods: The rats in the model (DAT) and medication administration (Rhizoma Paridis total saponins (RPTS) and Pennogenin (PN)) groups were given a high temperature and high humidity environment, high fat and high sugar diet combined with 2,4,6-trinitrobenzene sulfonic acid (TNBS) to establish the model of experimental colitis of damp-heat type, and the normal control group (RNC) rats were given a normal diet at normal temperature and humidity. Damp-heat control group (DNC) was set with the same condition as DAT without TNBS. Hematoxylin-Eosin (HE) staining was used to observe the histopathological morphology of the rat colorectum. The expression of the metabolism-related genes (Phospholipase A2 (sPLA2, cPLA2), and phosphatidylethanolamine N-methyltransferase (PEMT)) was assessed by using real-time quantitative PCR analysis (RT–qPCR). And the levels of the metabolism-related proteins (sPLA2, cPLA2), S100A8/9, Arg-1, and cytokines were detected by enzyme-linked immunosorbent assay (ELISA) kit. To investigate lipids and amino acids which closely associated with the IBD and IBD-DH, lipid pseudotargeted metabolomics with UHPLC-TQ/MS analysis method, as well as targeted quantitative amino acid analysis were performed. Results: Our data showed that RPTS (50 mg/kg) and PN (20 mg/kg) significantly ameliorated the severity of TNBS-induced colitis and downregulated the levels of circulating proinflammatory cytokines. Compared with RNC group, lipid pseudotargeted metabolomics demonstrated that glycerophospholipids, sphingolipids, carnitine, and glycerolipids were the four most perturbed lipid classes, and amino acids targeted metabolomics demonstrated that serine, N-acetylneuraminic acid, histidine, proline, taurine, and kynurenine changed significantly in DAT group . Correlation analyses showed tight associations between most of differential metabolites and proinflammatory cytokines. RPTS and PN both regulated glycerophospholipid metabolism and sphingolipid metabolism. However, both of them did not have a significant effect on amino acid modulation. RPTS and PN potentially regulated sPLA2, cPLA2, and PEMT. Conclusion: These results showed that RPTS (50 mg/kg) and PN (20 mg/kg) effectively alleviated rats’ colitis of damp-heat type, affected cytokines, and altered lipid metabolism without significant modulation on amino acid metabolism.

16 May 2026 in Annals of Medicine
Verified
Journal Article
Open access
WZWang Zhang
Wang Zhang
XWXingxing Wu
Xingxing Wu
YLYuge Li
Yuge Li
ZHZhenting Huang
Zhenting Huang
WHWenjia Hui
Wenjia Hui
JWJing Wu
Jing Wu
Coeliac disease (CeD) is a relatively common autoimmune disease in Caucasian populations, but is rarely reported in China. The metabolic characteristics of Chinese patients with coeliac disease remain insufficiently characterised. Therefore, this study attempted to describe the metabolic profile of a small cohort Chinese patients with coeliac disease. Plasma samples and dietary pattern information were collected from 15 patients with CeD, 15 healthy volunteers, and 30 patients with inflammatory bowel disease (IBD). Plasma metabolomic analysis was performed using a pseudo-targeted metabolomics approach based on ultra-high-performance liquid chromatography coupled with triple quadrupole-linear ion trap mass spectrometry (UHPLC-QTRAP-MS). Dietary intake was assessed via food frequency questionnaires, and metabolomics data were adjusted according to energy and 17 specific nutrient covariates. Despite reporting significantly higher daily intakes of protein and carbohydrate when compared to controls or IBD patients, CeD patients exhibited a relative insufficiency of micronutrient niacin. Several distinct metabolic alterations were identified in CeD patients relative to healthy controls, independent of dietary intake. These included decreased metabolites in the pentose phosphate pathway and increased intermediates of the citric acid cycle. The abundances of L-proline, D-proline, microbiota-related aromatic amino acid metabolites, glycine-conjugated bile acids, and the plant sterol panuosterone were increased. In contrast, the abundances of several long-chain acylcarnitines were reduced despite higher fat intake. These metabolic alterations existed in CeD but not in IBD patients. CeD patients in Northwest China exhibit a unique metabolic profile distinct from IBD and healthy controls, involving host central carbon metabolism, glycerophospholipid metabolism, gut microbiota, and other factors. This might underscore the multifactorial nature of coeliac disease, implicating other factors beyond genetics and gluten.